ABHD13

Across TCGA pan-cancer cohorts, ABHD13 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ABHD13 data layer compared with 18 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ABHD13 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ABHD13 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

UCEC, GBM, and PDAC are the cancer types where ABHD13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Quartile	III,IV	0.885	0.274	.006	20	view →
GBM	OS	Median	All	0.634	0.236	.001	16	view →
PDAC	DFS	Median	IV	0.752	0.250	.024	5	view →
HNSC	DFS	Median	II,III,IV	0.704	0.888	.018	3	view →
LSCC	DFS	Median	All	0.919	0.615	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ABHD13–UCEC (DFS)

Open the UCEC breakdown →